Raloxifene/SBE-β-CD Inclusion Complexes Formulated into Nanoparticles with Chitosan to Overcome the Absorption Barrier for Bioavailability Enhancement
Open Access
- 28 June 2018
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 10 (3) , 76
Abstract
Raloxifene (RXF) is a hormone-like medication used for treating postmenopausal osteoporosis and estrogen-dependent breast cancer, yet associated with bad low bioavailability due to poor solubility. This study was intended to develop cyclodextrin/chitosan nanoparticles (ccNPs) for oral delivery of RXF in order to enhance the oral bioavailability. RXF-loaded ccNPs (RXF-ccNPs) were prepared by cyclodextrin inclusion followed by complexation with chitosan. RXF-ccNPs were fully characterized by particle size, morphology and in vitro drug release. The oral delivery efficacy and transepithelial transport potential were evaluated by pharmacokinetics, in situ single-pass intestinal perfusion, cellular uptake and ex vivo imaging. The resulting RXF-ccNPs were around 165 nm in particle size with a narrow distribution. The oral bioavailability of RXF was enhanced by 2.6 folds through ccNPs compared to RXF suspensions in rats. It was shown that RXF-ccNPs could improve the intestinal permeability of RXF, increase the cellular uptake of RXF and facilitate its transport across the absorptive epithelia. The results indicate that our developed ccNPs based on sulfobutylether-β-cyclodextrin and oligochitosan are a promising vehicle to orally deliver poorly water-soluble drugs over and above RXF.Keywords
This publication has 29 references indexed in Scilit:
- Nanosuspensions Containing Oridonin/HP-β-Cyclodextrin Inclusion Complexes for Oral Bioavailability Enhancement via Improved Dissolution and PermeabilityAAPS PharmSciTech, 2015
- Scientific and Regulatory Standards for Assessing Product Performance Using the Similarity Factor, f2The AAPS Journal, 2015
- Preparation, characterization and in vivo evaluation of formulation of repaglinide with hydroxypropyl-β-cyclodextrinInternational Journal of Pharmaceutics, 2014
- Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia)Clinical Interventions in Aging, 2014
- Lipid nanoparticles for oral delivery of raloxifene: Optimization, stability, in vivo evaluation and uptake mechanismEuropean Journal of Pharmaceutics and Biopharmaceutics, 2014
- Poly (ε-caprolactone) nanocapsules for oral delivery of raloxifene: process optimization by hybrid design approach,in vitroandin vivoevaluationJournal of Microencapsulation, 2014
- Update on RaloxifeneObstetrical & Gynecological Survey, 2013
- Enhanced intestinal absorption and bioavailability of raloxifene hydrochloride via lyophilized solid lipid nanoparticlesAdvanced Powder Technology, 2013
- Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatmentTranslational Research, 2012
- Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: optimization and in vivo appraisalInternational Journal of Nanomedicine, 2012